Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.

Published online

Journal Article

First-line chemotherapy to combat primary malignant brain cancer is often accompanied by lymphopenic immunologic deficiency. Although counterintuitive, chemotherapy-induced lymphopenia can provide excellent host conditioning that may actually be leveraged to potentiate antitumor immunotherapy. We discuss here our preclinical and clinical experiences applying immunotherapy against glioblastoma, the most common and lethal primary malignant brain tumor, as well as the use of immunotherapeutics in the setting of standard-of-care temozolomide chemotherapy.

Full Text

Duke Authors

Cited Authors

  • Sanchez-Perez, L; Suryadevara, CM; Choi, BD; Reap, EA; Sampson, JH

Published Date

  • 2014

Published In

Volume / Issue

  • 3 / 7

Start / End Page

  • e944054 -

PubMed ID

  • 25610727

Pubmed Central ID

  • 25610727

International Standard Serial Number (ISSN)

  • 2162-4011

Digital Object Identifier (DOI)

  • 10.4161/21624011.2014.944054

Language

  • eng

Conference Location

  • United States